Blood
Blood
5 years ago

Effect of non-permissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T cell depletion.

Partow Kebriaei, Yudith Carmazzi, Katy Rezvani, Michelle Alvarez, Uday Popat, Amanda Olson, Sairah Ahmed, Marcos de Lima, Richard E Champlin, Gabriela Rondon, Elizabeth J Shpall, Martin Korbling, Issa Khouri, Betül Oran, Kai Cao, Yago Nieto, Chitra Hosing, Paolo Anderlini, Pedro Cano, Stefan Ciurea, Qasier Bashir, Amin Alousi, Rima M Saliba, Marcelo Fernandez-Vina, David Marin, Borje S Andersson, Muzaffar Qazilbash
We investigated the impact of donor-recipient HLA-DPB1 matching on outcomes of allogeneic hematopoietic stem cell transplantation with in vivo T cell depletion using ATG for patients with hematological malignancies. All donor-recipient pairs had high resolution typing for HLA-A, -B, -C, -DRB1, -DQB1, -DPB1 and -DRB3/4/5 and were matched at HLA-A, -B, -C and -DRB1. HLA-DPB1 mismatches were categorized by immunogenicity of the DPB1 matching using the DPB T-cell epitope tool. Of 1004 donor-recipient pairs, 210 (21%) were DPB1 matched, 443 (44%) had permissive mismatches, 184 (18%) non-permissive mismatches, in graft versus host (GvH) direction and 167 (17%) non-permissive mismatches in host versus graft (HvG) direction. Compared with HLA-DPB1 permissive mismatched pairs, non-permissive GvH mismatched pairs had the highest risk of grade II-IV acute graft versus host disease (aGvHD) (HR=1.4, p=0.01) while matched pairs had the lowest risk (HR=0.5, p<0.001). Grade III-IV aGvHD was only increased with non-permissive GvH mismatched (HR=2.3, p=0.005). The risk of disease progression was lower with any HLA-DPB1 mismatches, permissive or non-permissive However the favorable prognosis of HLA-DPB1 mismatches on disease progression was observed only in peripheral blood stem cell recipients that were in the intermediate risk group by the disease risk index (HR=0.4, p=0.001) but no other risk groups. Our results suggest avoidance of non-permissive GvH HLA-DPB1 mismatches for lowering the risk of grade II-IV and III-IV aGvHD. Permissive or non-permissive HvG HLA-DPB1 mismatches may be preferred over HLA-DPB1 matched donors in the intermediate risk patients to decrease the risk of disease progression.

Publisher URL: http://doi.org/10.1182/blood-2017-07-798751

DOI: 10.1182/blood-2017-07-798751

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.